Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer

Molecular and Cellular Endocrinology

Volumn 360, Issue 1-2, 2012, Pages 68-75

  Eichholz, Andrew ^a   Ferraldeschi, Roberta ^a   Attard, Gerhardt ^a   De Bono, Johann S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Abiraterone; Heat shock proteins; MDV3100; OGX 427; Orteronel (TAK 700); VN 124 1 (TOK 001)

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; ALVESPIMYCIN; ANDROGEN RECEPTOR; BICALUTAMIDE; CYTOCHROME P450 17; DEXAMETHASONE; DOCETAXEL; GALETERONE; GANETESPIB; GELDANAMYCIN; HEAT SHOCK PROTEIN; KETOCONAZOLE; OGX 427; ORTERONEL; PLACEBO; PREDNISONE; PROTEIN INHIBITOR; RETASPIMYCIN; TANESPIMYCIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANDROGEN SYNTHESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; ENZYME INHIBITION; FATIGUE; FLUID RETENTION; HEART DISEASE; HUMAN; HYPERTENSION; HYPOKALEMIA; INTRACELLULAR SIGNALING; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HEAT-SHOCK PROTEINS; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STEROID 17-ALPHA-HYDROXYLASE;

EID: 84864003814     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.09.038     Document Type: Review

References (67)

1. Attard G., Reid A.H., A'hern R., Parker C., Oommen N.B., Folkerd E., Messiou C., Molife L.R., Maier G., Thompson E., Olmos D., Sinha R., Lee G., Dowsett M., Kaye S.B., Dearnaley D., Kheoh T., Molina A., De Bono J.S. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 2009, 27:3742-3748.
2. Attard G., Swennenhuis J.F., Olmos D., Reid A.H., Vickers E., A'hern R., Levink R., Coumans F., Moreira J., Riisnaes R., Oommen N.B., Hawche G., Jameson C., Thompson E., Sipkema R., Carden C.P., Parker C., Dearnaley D., Kaye S.B., Cooper C.S., Molina A., Cox M.E., Terstappen L.W., De Bono J.S. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009, 69:2912-2918.
3. Barrie S.E., Potter G.A., Goddard P.M., Haynes B.P., Dowsett M., Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J. Steroid. Biochem. Mol. Biol. 1994, 50:267-273.
4. Bergerat J.P., Ceraline J. Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Hum. Mutat. 2009, 30:145-157.
5. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10:33-39.
6. Danila D.C., Morris M.J., De Bono J.S., Ryan C.J., Denmeade S.R., Smith M.R., Taplin M.E., Bubley G.J., Kheoh T., Haqq C., Molina A., Anand A., Koscuiszka M., Larson S.M., Schwartz L.H., Fleisher M., Scher H.I. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 2010, 28:1496-1501.
7. De Billy E., Powers M.V., Smith J.R., Workman P. Drugging the heat shock factor 1 pathway Exploitation of the critical cancer cell dependence on the guardian of the proteome. Cell Cycle 2009, 8:3806-3808.
8. De Bono, J.S., Logothetis, C.J., Fizazi, K., North, S., Chu, L., Chi, K.N., Kheoh, T., Haqq, C., Molina, A., Scher, H.I., 2010a. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (PTS) with metastatic castration-resistant prostate cancer (MCRPC) who have progressed after docetaxel-based chemotherapy (CHEMO): Results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. Ann. Oncol., 21, viii2.
9. De Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I., Gravis G., Bodrogi I., Mackenzie M.J., Shen L., Roessner M., Gupta S., Sartor A.O. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
10. Dehm S.M., Schmidt L.J., Heemers H.V., Vessella R.L., Tindall D.J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008, 68:5469-5477.
11. Dreicer, R., Agus, D.B., Macvicar, D., Maclean, D., Zhang, T., Stadler, W.M., 2010. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: A phase I/II, open-label study. 2010 Genitourinary Cancers Symposium, San Francisco, CA.
12. Edwards J., Krishna N.S., Grigor K.M., Bartlett J.M. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer 2003, 89:552-556.
13. Elo J.P., Kvist L., Leinonen K., Isomaa V., Henttu P., Lukkarinen O., Vihko P. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J. Clin. Endocrinol. Metab. 1995, 80:3494-3500.
14. Feng S., Tang Q., Sun M., Chun J.Y., Evans C.P., Gao A.C. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol. Cancer Ther. 2009, 8:665-671.
15. Figg W.D., Sartor O., Cooper M.R., Thibault A., Bergan R.C., Dawson N., Reed E., Myers C.E. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am. J. Med. 1995, 98:412-414.
16. Gan L., Chen S., Wang Y., Watahiki A., Bohrer L., Sun Z., Huang H. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 2009, 69:8386-8394.
17. Georget V., Terouanne B., Nicolas J.C., Sultan C. Mechanism of antiandrogen action: Key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 2002, 41:11824-11831.
18. Goetz M.P., Toft D., Reid J., Ames M., Stensgard B., Safgren S., Adjei A.A., Sloan J., Atherton P., Vasile V., Salazaar S., Adjei A., Croghan G., Erlichman C. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J. Clin. Oncol. 2005, 23:1078-1087.
19. Grad J.M., Dai J.L., Wu S., Burnstein K.L. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. Mol. Endocrinol. 1999, 13:1896-1911.
20. Gregory C.W., He B., Johnson R.T., Ford O.H., Mohler J.L., French F.S., Wilson E.M. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001, 61:4315-4319.
21. Guo Z., Yang X., Sun F., Jiang R., Linn D.E., Chen H., Kong X., Melamed J., Tepper C.G., Kung H.J., Brodie A.M., Edwards J., Qiu Y. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009, 69:2305-2313.
22. Heath E.I., Hillman D.W., Vaishampayan U., Sheng S.J., Sarkar F., Harper F., Gaskins M., Pitot H.C., Tan W., Ivy S.P., Pili R., Carducci M.A., Erlichman C., Liu G. A phase II trial of 17-Allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 2008, 14:7940-7946.
23. Hellerstedt B.A., Pienta K.J. The current state of hormonal therapy for prostate cancer. CA Cancer J. Clin. 2002, 52:154-179.
24. Hotte S.J., Yu E.Y., Hirte H.W., Higano C.S., Gleave M., Chi K.N. OGX-427, a 2' methoxyethyl antisense oligonucleotide (ASO), against HSP27: results of a first-in-human trial. J. Clin. Oncol. 2009, 27:3506.
25. Huggins C., Hodges C.V. Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941, 1:293-297.
26. Kamischke A., Kemper D.E., Castel M.A., Luthke M., Rolf C., Behre H.M., Magnussen H., Nieschlag E. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur. Respir. J. 1998, 11:41-45.
27. Kuroda K., Liu H., Kim S., Guo M., Navarro V., Bander N.H. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 2009, 69:1579-1585.
28. Labrie C., Cusan L., Plante M., Lapointe S., Labrie F. Analysis of the androgenic activity of synthetic " progestins" currently used for the treatment of prostate cancer. J. Steroid. Biochem. 1987, 28:379-384.
29. Laitinen S., Karhu R., Sawyers C.L., Vessella R.L., Visakorpi T. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. Genes Chromo. Cancer 2002, 35:66-73.
30. Lee H.J., Chang C. Recent advances in androgen receptor action. Cell. Mol. Life Sci. 2003, 60:1613-1622.
31. Linja M.J., Savinainen K.J., Saramaki O.R., Tammela T.L., Vessella R.L., Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001, 61:3550-3555.
32. Mahalingam D., Swords R., Carew J.S., Nawrocki S.T., Bhalla K., Giles F.J. Targeting HSP90 for cancer therapy. Brit. J. Cancer 2009, 100:1523-1529.
33. Maloney A., Clarke P.A., Naaby-Hansen S., Stein R., Koopman J.O., Akpan A., Yang A., Zvelebil M., Cramer R., Stimson L., Aherne W., Banerji U., Judson I., Sharp S., Powers M., Debilly E., Salmons J., Walton M., Burlingame A., Waterfield M., Workman P. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 2007, 67:3239-3253.
34. Matsunaga N., Kaku T., Ojida A., Tanaka T., Hara T., Yamaoka M., Kusaka M., Tasaka A. C(17, 20)-lyase inhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17, 20)-lyase inhibitors. Bioorg. Med. Chem. 2004, 12:4313-4336.
35. Mohler J.L., Gregory C.W., Ford O.H., Kim D., Weaver C.M., Petrusz P., Wilson E.M., French F.S. The androgen axis in recurrent prostate cancer. Clin. Cancer Res. 2004, 10:440-448.
36. Mostaghel E.A., Page S.T., Lin D.W., Fazli L., Coleman I.M., True L.D., Knudsen B., Hess D.L., Nelson C.C., Matsumoto A.M., Bremner W.J., Gleave M.E., Nelson P.S. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007, 67:5033-5041.
37. Nishiyama T., Hashimoto Y., Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin. Cancer Res. 2004, 10:7121-7126.
38. O'donnell A., Judson I., Dowsett M., Raynaud F., Dearnaley D., Mason M., Harland S., Robbins A., Halbert G., Nutley B., Jarman M. Hormonal impact of the 17alpha-hydroxylase/C(17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer 2004, 90:2317-2325.
39. Oh, W.K., Stadler, W.M., Srinivas, S., Chu, F., Bubley, G., Quigley, M., Goddard, J., Dunbar, J., Grayzel, D., Ross, R.W., 2009. A single arm phase II trial of IPI-504 in patients with castration resistant prostate cancer (CRPC). In: 2009 Genitourinary Cancers Symposium, 2009 Orlando, FL.
40. Pacey S.C., Wilson R., Walton M., Eatock M., Zetterlund A., Arkenau H., Beecham R., Raynaud F., Workman P., Judson I. A phase I trial of the HSP90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours. J. Clin. Oncol. 2009, 27:3534.
41. Powers M.V., Clarke P.A., Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008, 14:250-262.
42. Powers M.V., Jones K., Barillari C., Westwood I., Van Montfort R.L.M., Workman P. Targeting HSP70 The second potentially druggable heat shock protein and molecular chaperone?. Cell Cycle 2010, 9:1542-1550.
43. Powers M.V., Workman P. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett. 2007, 581:3758-3769.
44. Prescott J., Coetzee G.A. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett. 2006, 231:12-19.
45. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000, 355:1491-1498. Prostate Cancer Trialists' Collaborative Group.
46. Reid A.H., Attard G., Danila D.C., Oommen N.B., Olmos D., Fong P.C., Molife L.R., Hunt J., Messiou C., Parker C., Dearnaley D., Swennenhuis J.F., Terstappen L.W., Lee G., Kheoh T., Molina A., Ryan C.J., Small E., Scher H.I., De Bono J.S. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 2010, 28:1489-1495.
47. Rocchi P., Beraldi E., Ettinger S., Fazli L., Vessella R.L., Nelson C., Gleave M. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res. 2005, 65:11083-11093.
48. Rocchi P., So A., Kojima S., Signaevsky M., Beraldi E., Fazli L., Hurtado-Coll A., Yamanaka K., Gleave M. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res. 2004, 64:6595-6602.
49. Ryan C.J., Smith M.R., Fong L., Rosenberg J.E., Kantoff P., Raynaud F., Martins V., Lee G., Kheoh T., Kim J., Molina A., Small E.J. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol. 2010, 28:1481-1488.
50. Saporita A.J., Ai J.K., Wang Z. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 2007, 67:509-520.
51. Schayowitz A., Sabnis G., Njar V.C., Brodie A.M. Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Mol. Cancer Ther. 2008, 7:121-132.
52. Schellhammer P.F., Sharifi R., Block N.L., Soloway M.S., Venner P.M., Patterson A.L., Sarosdy M.F., Vogelzang N.J., Schellenger J.J., Kolvenbag G.J. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex combination study group. Urology 1997, 50:330-336.
53. Scher H.I., Beer T.M., Higano C.S., Anand A., Taplin M.E., Efstathiou E., Rathkopf D., Shelkey J., Yu E.Y., Alumkal J., Hung D., Hirmand M., Seely L., Morris M.J., Danila D.C., Humm J., Larson S., Fleisher M., Sawyers C.L. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375:1437-1446.
54. Scher H.I., Kelly W.K. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol. 1993, 11:1566-1572.
55. Small E.J., Halabi S., Dawson N.A., Stadler W.M., Rini B.I., Picus J., Gable P., Torti F.M., Kaplan E., Vogelzang N.J. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J. Clin. Oncol. 2004, 22:1025-1033.
56. Small E.J., Srinivas S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 1995, 76:1428-1434.
57. Solit D.B., Zheng F.Z.F., Drobnjak M., Munster P.N., Higgins B., Verbel D., Heller G., Tong W., Cordon-Cardo C., Agus D.B., Scher H.I., Rosen N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res. 2002, 8:986-993.
58. Tan J., Sharief Y., Hamil K.G., Gregory C.W., Zang D.Y., Sar M., Gumerlock P.H., Devere White R.W., Pretlow T.G., Harris S.E., Wilson E.M., Mohler J.L., French F.S. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol. Endocrinol. 1997, 11:450-459.
59. Tannock I., Gospodarowicz M., Meakin W., Panzarella T., Stewart L., Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J. Clin. Oncol. 1989, 7:590-597.
60. Tannock I.F., De Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Theodore C., James N.D., Turesson I., Rosenthal M.A., Eisenberger M.A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351:1502-1512.
61. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., Wongvipat J., Smith-Jones P.M., Yoo D., Kwon A., Wasielewska T., Welsbie D., Chen C.D., Higano C.S., Beer T.M., Hung D.T., Scher H.I., Jung M.E., Sawyers C.L. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
62. Tsui K.H., Feng T.H., Hsieh W.C., Chang P.L., Juang H.H. Expression of interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells. Acta Pharmacol. Sin. 2008, 29:1334-1341.
63. Vanaja D.K., Mitchell S.H., Toft D.O., Young C.Y.F. Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaper. 2002, 7:55-64.
64. Vasaitis T., Belosay A., Schayowitz A., Khandelwal A., Chopra P., Gediya L.K., Guo Z., Fang H.B., Njar V.C., Brodie A.M. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17, 20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5, 16-diene in prostate cancer. Mol. Cancer Ther. 2008, 7:2348-2357.
65. Watson P.A., Chen Y.F., Balbas M.D., Wongvipat J., Socci N.D., Viale A., Kim K., Sawyers C.L. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc. Natl. Acad. Sci. USA 2010, 107:16759-16765.
66. Wu F.C., Tajar A., Pye S.R., Silman A.J., Finn J.D., O'neill T.W., Bartfai G., Casanueva F., Forti G., Giwercman A., Huhtaniemi I.T., Kula K., Punab M., Boonen S., Vanderschueren D. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European male aging study. J. Clin. Endocrinol. Metab. 2008, 93:2737-2745.
67. Zoubeidi A., Zardan A., Beraldi E., Fazli L., Sowery R., Rennie P., Nelson C., Gleave M. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res. 2007, 67:10455-10465.